Showing 1716 results
-
Press release /Phase I/II study to evaluate Mekinist® (trametinib) in combination with Opdivo® (nivolumab) and Opdivo + Yervoy® (ipilimumab) Collaboration expands upon existing clinical investigation of…
-
Press release /Urgent need to improve management of chronic urticaria (CU) - a disease that causes itchy, persistent hives and swelling which last more than 6 weeks or recur over months or years - highlighted by…
-
Ad hoc release /Net sales grew 5% (cc[1], +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD…
-
Press release /Novartis and Medicines for Malaria Venture (MMV) announce decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malariaThis novel combination also contains an…
-
Press release /The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1Safety in GCA patients was consistent with known safety profile…
-
Press release /New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide®* to Ultibro® Breezhaler® improved lung function and was well tolerated. The FLASH…
-
Press release /Post-hoc analysis of PARADIGM-HF published in JAMA Cardiology shows heart failure patients treated with Entresto experience significant improvements in physical and social activities compared to…
-
Press release /Ultibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with lung hyperinflation, compared to placebo CLAIM is the first study to…
-
Press release /New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus…
-
Press release /NEPTUNUS-1 and NEPTUNUS-2 achieved primary objective of reduced disease activity and provided clinically meaningful benefit1 Data showed consistent improvements across secondary…